Home > Riviste > Minerva Dental and Oral Science > Fascicoli precedenti > Minerva Dental and Oral Science 2022 June;71(3) > Minerva Dental and Oral Science 2022 June;71(3):163-7



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo



Minerva Dental and Oral Science 2022 June;71(3):163-7

DOI: 10.23736/S2724-6329.21.04458-2


lingua: Inglese

The use of mandibular advancement devices in adult patients affected by obstructive sleep apnea syndrome: our experience with Thornton Adjustable Positioner® splint

Francesco CAVARRA 1, Paolo BOFFANO 2 , Gerardo TRICARICO 1, Michele TEPEDINO 3, Matteo BRUCOLI 2, 4, Vincenzo ROCCHETTI 1, 4

1 Sant’Andrea Hospital, Vercelli, Italy; 2 Maggiore della Carità Hospital, Novara, Italy; 3 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy; 4 University of Eastern Piedmont, Novara, Italy

BACKGROUND: Obstructive sleep apnea syndrome (OSAS) is a sleep-related disorder resulting in apneic and hypopneic episodes during sleep. The purpose of this article was to present and discuss our experience with the Thornton Adjustable Positioner® (TAP) Splint (Scheu-Dental GmbH, Iserlohn, Germany; Orthosystem, Milan, Italy) in a consecutive series of patients affected by OSAS.
METHODS: The data of all patients affected by OSAS and with indication to oral appliance (OA) treatment at the Department of Dentistry of the Hospital of Vercelli between January 1, 2019, and December 31, 2019, were collected. The following data were recorded for each patient: gender, age, smoke and/or alcohol assumption, BMI, comorbidities and current pharmacological therapy, initial AHI, OSAS category, eventual performed OSAS treatment options before OA treatment, indication to OA treatment, final AHI following OA treatment, complications and side effects.
RESULTS: A total of 18 subjects (11 men, 7 women) with a mean age of 58.8 years were enrolled in this study with a mean AHI of 27.9 (range 5.884). Average BMI was 29. OA treatment reduced AHI in all patients (mean post treatment AHI: 5; range: 3.1-8). All patients were satisfied with the subjective improvement of OSAS symptoms.
CONCLUSIONS: Our results confirm the usefulness of a specific type of mandibular advancement device that can be considered as a valuable therapeutic modality in OSAS patients. Side effects are limited, and they usually do not decrease the compliance of patients.

KEY WORDS: Sleep apnea, obstructive; Mandibular advancement; Apnea

inizio pagina